Each year, CCR licenses new technologies, publishes articles in peer-reviewed journals, opens new clinical trials and brings in thousands of patients and trainees. Take a look at our year as told by the numbers.
- ~1500Articles in peer-reviewed journals
- ~1000Trainees
- 70New Employee Invention Reports
- 57Issued U.S. patents
- 655Active licenses
- 183Active Cooperative Research and Development Agreements (CRADAs)
- 245Clinical trials
- 1403New patients
- 58New trials opening
CCR Products:
Vaccines and Therapeutics
- 2-F-Ara-Fludara, Berlex
- Videx®, Berlex
- Hivid®, BMS
- Paclitaxel®, BMS
- Trimetrexate- Neu Trexin, US Bioscience
- Zenapax®, Hoffman La Roche
- Vitravene®, Isis Pharma
- Zevalin®, IDEC Pharma
- Kepivance®, Amgen
- Gardasil®, Merck
- Prezista®, Tibotec Pharma
- Cervarix®, GSK
- Lumoxiti®, Innate Pharma
- *Avelumab, Pfizer
- *Istodax®, Celgene
- *Voraxaze®, BTG
- *Avastin®, Genentech
- *YescartaTM, Kite Pharma
- *Selumetinib, AstraZeneca
- *POMALYST®, Bristol Myers Squibb
- *CCR clinical trial testing
Diagnostics
- Diagnostic test for HIV-1
- Diagnostic test for HTLV-1
- DNA Probe for Breast Cancer
- Multi-Replica Blotting Kit for Proteins
Instrumentation/Devices
- Laser Capture Microdissection
- UroNav
*denotes CCR clinical trial testing